Loading…
Opus Genetics, Inc. is projected to rise to $4.39 by 2027, a +12% move from its current price of $3.92. IRD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.80 | $3.92 | $4.05 | +0.01% |
| Jul 14 | $3.75 | $3.92 | $4.11 | +0.03% |
| Jul 15 | $3.71 | $3.92 | $4.15 | +0.04% |
| Jul 16 | $3.68 | $3.92 | $4.18 | +0.06% |
| Jul 17 | $3.65 | $3.92 | $4.22 | +0.07% |
| Jul 18 | $3.62 | $3.92 | $4.25 | +0.08% |
| Jul 19 | $3.60 | $3.92 | $4.28 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.60 | $3.92 | $4.28 | +0.10% |
| Week 2 | $3.48 | $3.93 | $4.43 | +0.20% |
| Week 3 | $3.39 | $3.93 | $4.56 | +0.30% |
| Week 4 | $3.32 | $3.94 | $4.67 | +0.40% |
| Week 5 | $3.25 | $3.94 | $4.77 | +0.50% |
| Week 6 | $3.20 | $3.94 | $4.87 | +0.59% |
| Week 7 | $3.15 | $3.95 | $4.95 | +0.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other ophthalmic disorders. Its programs include OPGx-LCA5, in Phase 1/2 for LCA5-associated IRD, and OPGx-BEST1 for BEST1-associated retinal disease.
It also advances pre-clinical IRD programs such as OPGx-RHO, OPGx-RDH12, OPGx-MERTK, OPGx-NMNAT1, and OPGx-CNGB1, along with Phentolamine Ophthalmic Solution for reversal of mydriasis and for presbyopia and night vision disturbances, and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc.
and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
IRD is the entity’s stock, with a current price of $4.00 and a market cap of $330.26M. It ranks 3401 by market capitalization among listed securities. The price outlook is defined by a year-by-year forecast, starting with a 2026 average of $4.00 (range $1.93 to $5.08, 0% ROI) and extending through 2050, where the average is $44.65 with a max of $95.44 and a 1016.4% ROI.
The forecast depicts a path of rising averages and substantial upside over the long term, alongside a 30-day technical picture that informs near-term momentum.
A major floor 19.4% below — a decisive break under it would weaken the trend.
The nearest floor, 5.4% below — buyers have tended to step in here.
The nearest ceiling, 18.4% above — a clean break opens room to run.
A major ceiling 46.7% above — clearing it would confirm fresh momentum.
Key IRD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IRD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.03 | Sell | $4.02 | Sell |
| MA 10 | $4.07 | Sell | $4.04 | Sell |
| MA 20 | $4.01 | Sell | $4.07 | Sell |
| MA 50 | $4.35 | Sell | $4.24 | Sell |
| MA 100 | $4.53 | Sell | $4.11 | Sell |
| MA 200 | $3.34 | Buy | $3.52 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.06 | Neutral |
| Stoch RSI (14) | 41.12 | Neutral |
| CCI (20) | -60.97 | Neutral |
| Williams %R (14) | -59.62 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -3.92 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 40.38 | Neutral |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 37.26 | Neutral |
| Momentum (10) | 0.20 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 3.99 | Sell |
| ADX (14) | 12.02 | Neutral |
| ATR (14) | 0.11 | Info |
Technically, the 30-day picture shows a bullish tilt with RSI14 at 40. The 50-day simple moving average sits at $4.62 while the 200-day simple moving average sits at $3.21. Key near-term levels are a support at $3.71 and a resistance at $5.03.
The 30-day price range spans from a low of $3.10 to a high of $5.16. Annualized volatility is elevated at 70%, underscoring the near-term price swings that can occur.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.93 | $3.92 | $5.00 | 0% | Neutral | |
| $3.43 | $4.39 | $5.97 | +12% | Neutral | |
| $3.92 | $5.19 | $7.36 | +32% | Bullish | |
| $5.09 | $6.92 | $10.17 | +77% | Bullish | |
| $5.69 | $7.94 | $11.98 | +102% | Bullish | |
| $5.77 | $8.23 | $12.73 | +110% | Bullish | |
| $6.10 | $8.89 | $14.06 | +127% | Bullish | |
| $6.21 | $9.23 | $14.88 | +135% | Bullish | |
| $6.96 | $10.55 | $17.31 | +169% | Bullish | |
| $8.39 | $12.96 | $21.62 | +231% | Bullish | |
| $10.95 | $18.41 | $32.92 | +370% | Bullish | |
| $19.22 | $37.50 | $74.16 | +857% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.93 | $3.92 | $4.83 | +0.00% |
| August 2026 | $3.39 | $4.02 | $4.91 | +2.51% |
| September 2026 | $3.32 | $3.97 | $4.91 | -1.19% |
| October 2026 | $3.40 | $4.09 | $5.12 | +3.06% |
| November 2026 | $3.40 | $4.12 | $5.20 | +0.61% |
| December 2026 | $3.22 | $3.92 | $5.00 | -4.67% |
Click any year to see its month-by-month IRD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IRD price prediction for 2026 points to an average of $3.92 (low $1.93, high $5.00) — a potential gain of 0% on today's $3.92. Price action looks broadly range-bound.
In 2027, IRD is projected to trade between $3.43 and $5.97, averaging $4.39 — a potential gain of +12% from today's $3.92. That is up +12% on the projected 2026 average. A consolidation phase looks the most probable path here.
Opus Genetics, Inc.'s 2028 outlook centres on $5.19, within a $3.92 to $7.36 range. That is up +18% on the projected 2027 average. That marks a +32% change versus current levels. Momentum favours further upside here.
By 2029, IRD could reach as high as $10.17, with a base case around $6.92 and support toward $5.09 — roughly +77% from $3.92. Buyers look set to stay in control over this stretch.
Expect IRD to range from $5.69 to $11.98 through 2030. The $7.94 average target implies a +102% move from current prices. That is up +15% on the projected 2029 average. Momentum favours further upside here.
The IRD price prediction for 2031 points to an average of $8.23 (low $5.77, high $12.73) — a potential gain of +110% on today's $3.92. Buyers look set to stay in control over this stretch.
In 2032, IRD is projected to trade between $6.10 and $14.06, averaging $8.89 — a potential gain of +127% from today's $3.92. That is up +8% on the projected 2031 average. Momentum favours further upside here.
Opus Genetics, Inc.'s 2033 outlook centres on $9.23, within a $6.21 to $14.88 range. That is up +4% on the projected 2032 average. That marks a +135% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IRD could reach as high as $17.31, with a base case around $10.55 and support toward $6.96 — roughly +169% from $3.92. Momentum favours further upside here.
Expect IRD to range from $8.39 to $21.62 through 2035. The $12.96 average target implies a +231% move from current prices. That is up +23% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The IRD price prediction for 2040 points to an average of $18.41 (low $10.95, high $32.92) — a potential gain of +370% on today's $3.92. Momentum favours further upside here.
In 2050, IRD is projected to trade between $19.22 and $74.16, averaging $37.50 — a potential gain of +857% from today's $3.92. That is up +104% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IRD today (≈ 255.102041 IRD) could be worth
$9,567.33
+$8,567.33 (+857%) by 2050 · US Dollar
Based on the average projected IRD price of $37.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IRDwould be worth at today's price.
$1,000 invested in IRD on Jul 10, 2025 (≈ 892.857139 IRD) would be worth
$3,500
+$2,500 (+250.0%) today · 3.50× · US Dollar
Based on a IRD entry price of $1.12 vs. today's $3.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.23 | $926.71 | -7.3% |
| 1 month ago | $3.89 | $1,007.71 | +0.8% |
| 3 months ago | $5.36 | $731.34 | -26.9% |
| 6 months ago | $2.05 | $1,912.2 | +91.2% |
| 1 year ago | $1.12 | $3,500 | +250.0% |
| All time (5.0y) ago | $4.2 | $933.33 | -6.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IRD forecast.
Our base-case forecast reaches $7.80 around 2030.
Implied market cap at $7.80: $644.01M
The multi-year forecast traces a steadily higher path from 2026 onward, with each year’s expected average price generally rising and bullish sentiment predominating from 2027 onward. In 2027 the average is $4.66 with a 16.6% ROI. In 2028 the average is $5.57 with a 39.4% ROI, and in 2029 the average is $7.67 with a 91.7% ROI.
By 2030 the average is $9.06 and the ROI is 126.5%. The path continues with 2031 at $9.04 (125.9%), 2032 at $9.92 (148%), 2033 at $10.63 (165.6%), 2034 at $11.86 (196.4%), and 2035 at $15.34 (283.4%). Looking further out, 2040 shows an average of $21.90 with a 447.4% ROI, and 2050 shows an average of $44.65 with a 1016.4% ROI and a max forecast of $95.44.
These are estimates and not guarantees, with higher volatility implied by the long-horizon projections.
Tap a question to reveal the answer.
For 2030, the forecast shows an average price of $9.06 with a range from $6.22 to $14.31 and a ROI of 126.5%, with sentiment listed as BULLISH.
Forecasts indicate a bullish trajectory from 2027 onward, with rising averages through 2030 and beyond (e.g., 2030 avg $9.06; 2040 avg $21.90; 2050 avg $44.65) and positive ROIs up to 1016.4%. These are estimates, not guarantees, and should be weighed with appropriate caution.
Yes. The 2040 forecast max is $41.87 and the 2050 forecast max is $95.44, with 2050 average $44.65, indicating a path that could exceed $40 in the model’s horizon.
The current price is $4.00 and the market cap is $330.26M.
The sentiment is BULLISH with RSI14 at 40. The 50-day SMA is $4.62 and the 200-day SMA is $3.21. Support is at $3.71 and resistance at $5.03. The 30-day range is $3.10 to $5.16, with annualized volatility at 70%.
Opus Genetics, Inc. Community Discussion
0Share your Opus Genetics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.